{"id":71418,"title":"Omega Diagnostics Gp (ODX.L) Update on progress of UK-Rapid Test Consortium","publisher":"Share Talk","author":"sharetalk","published":"2020-06-03T10:27:27+00:00","modified":"2020-06-03T10:27:27+00:00","canonical_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-update-on-progress-of-uk-rapid-test-consortium/","markdown_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-update-on-progress-of-uk-rapid-test-consortium.md","json_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-update-on-progress-of-uk-rapid-test-consortium.json","category":"Healthcare","categories":["Healthcare"],"tags":["allergy testing","antibody test","Colin King","COVID-19","Memorandum of Understanding","ODX","Omega Diagnostics Gp","Rapid Test","University of Oxford"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Significant progress in development with design freeze expected in June**\n\n**Omega (AIM: ODX)**, the medical diagnostics company focused on CD4, food intolerance and allergy testing, notes the Press Release issued today by UK Rapid Test Consortium (“UK-RTC”) on developing a COVID-19 lateral flow antibody test (“COVID-19 Rapid Test”) that can be used by people in their homes.\n\nAs announced on 9 April 2020, the Company signed a Memorandum of Understanding (“MOU”) with Abingdon Health Limited, BBI Solutions Limited, CIGA Healthcare Limited, in conjunction with the University of Oxford to form the UK-RTC in order to jointly develop and manufacture a COVID-19 Rapid Test as part of the Government’s five pillar national testing strategy for COVID-19.\n\nAs lead partner of the UK-RTC, Abingdon Health Limited has been developing the COVID-19 Rapid Test and the Company notes the significant progress made to date in such a short period of time. The Company’s role as a member of the UK-RTC is unchanged in that it is providing development support where required and will provide volume manufacturing capacity of the COVID-19 Rapid Test once design freeze has been attained by Abingdon Health and they have successfully transferred the manufacturing protocols to the Company.\n\nOmega will provide a further update once design freeze of the COVID-19 Rapid Test has been reached, a key milestone that the consortium hopes will be attained in June.\n\nThe UK-RTC Press Release is provided in full at the end of this announcement.\n\n**Colin King, CEO of Omega commented:** “I am really impressed with the progress Abingdon have made to date with the development in such a short period of time. Everyone is working extremely hard to deliver a high-quality product as soon as possible to help play a part in returning life back to more normal levels in the UK. ”\n\nThe information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014."}